The initiative will provide practical insights into understanding of obesity pathophysiology and its management.

Eli Lilly and Company (India), in collaboration with the Association of Physicians of India (API), on Friday announced the ...

Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...

For Novo, the Morgan Stanley team expects obesity revenues of $11.7 billion in 2030, while Lilly’s tirzepatide—assuming it clinches an obesity green light—could make around $5.4 billion over ...

The drugmaker also enlisted agency partner FleishmanHillard and actress Queen Latifah for its Inclusive Obesity Care Initiative to reduce the stigma for people living with obesity. Like Lilly, Novo’s ...

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b trial, according to data published in The New England Journal of Medicine ...

Eli Lilly received FDA approval to sell tirzepatide for obesity treatment, expanding its market beyond diabetes. Shares of Eli Lilly jumped 3.2% on the news, resulting in a $17.3 billion increase ...